María-Ángeles Montalbán

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

María‐Victoria Mateos, Albert Oriol, Joaquín Martínez‐López et al. · The Lancet Oncology · 2010 · 459 citations · Full text

Medicine, Hematology, Pharmacology +17

High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Bruno Paiva, Norma C. Gutiérrez, Laura Rosiñol et al. · Blood · 2011 · 304 citations · Full text

Medicine, Hematology, Oncology +17

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

Bruno Paiva, Joaquín Martínez‐López, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2011 · 233 citations · Full text

Medicine, Hematology, Oncology +13

Prognostic Value of Immunophenotyping in Multiple Myeloma: A Study by the PETHEMA/GEM Cooperative Study Groups on Patients Uniformly Treated With High-Dose Therapy

Gema Mateo, María-Ángeles Montalbán, María‐Belén Vídriales et al. · Journal of Clinical Oncology · 2008 · 210 citations · Full text

Medicine, Hematology, Oncology +16

Critical evaluation of ASO RQ-PCR for minimal residual disease evaluation in multiple myeloma. A comparative analysis with flow cytometry

Noemí Puig, María Eugenia Sarasquete, Ana Balanzategui et al. · Leukemia · 2013 · 170 citations

Medicine, Hematology, Pathology +16